A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition: Metastatic Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: ADI-PEG 20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Safety and Feasibility of Immuno-OCT
Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia Intervention: Drug: Bevacizumab-800CW Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition: Metastatic Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: ADI-PEG 20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Safety and Feasibility of Immuno-OCT
Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia Intervention: Drug: Bevacizumab-800CW Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition: Metastatic Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: ADI-PEG 20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Safety and Feasibility of Immuno-OCT
Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia Intervention: Drug: Bevacizumab-800CW Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition: Metastatic Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: ADI-PEG 20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Safety and Feasibility of Immuno-OCT
Conditions: Colon Carcinoma; Barrett Esophagus; Gastrointestinal Dysplasia Intervention: Drug: Bevacizumab-800CW Sponsor: University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)
Condition: Lung Cancer Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Drug: ADI-PEG 20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials